How to verify Sirolimus Rx quality before you buy

Last updated 2026-07-27

What does 'verifying quality' actually mean for sirolimus?

It means two separate things, and buyers routinely mix them up. One is drug quality: is the pill or vial actually sirolimus, at the labeled strength, made under controls that catch contamination or dosing errors. The other is evidence quality: does sirolimus actually do what's claimed for longevity. This article is mostly about the first question, because the second one has an honest, short answer: nobody knows yet in humans. Sirolimus (the generic name) and rapamycin (the original name, after Rapa Nui, where the source bacterium was found) are the same molecule ^[1]. Rapamune is the FDA-approved brand name tablet and oral solution, approved in 1999 for preventing organ transplant rejection ^[2]. Two other branded forms exist for narrow, unrelated indications: Fyarro (albumin-bound sirolimus, for a rare soft-tissue cancer) and Hyftor (topical sirolimus gel, for facial angiofibromas in tuberous sclerosis) ^[3]. None of the three is FDA-approved for aging, lifespan extension, or general longevity use. Every low-dose, intermittent-dosing protocol you've read about on longevity forums is off-label, meaning a prescriber is legally allowed to prescribe an approved drug for an unapproved use, but the FDA has not reviewed or approved that use ^[4]. So when you 'verify quality,' you're really checking: is the underlying chemical entity handled the way a regulated drug for immunosuppression should be, even when it's being used off-label at a lower dose for a different purpose.

Is sirolimus FDA-approved, and does that protect me if I buy it off-label?

Yes and no. Sirolimus itself is FDA-approved (as Rapamune, since 1999) ^[2], which means the manufacturing standards for the active ingredient are real and enforced by law. But FDA approval attaches to a specific product, dose, and indication, not to every use of the molecule. When a compounding pharmacy makes a custom capsule or vial at 3mg or 5mg for weekly off-label dosing, that specific preparation was never reviewed by the FDA for safety or efficacy at that dose or for that purpose. Compounded drugs are regulated differently. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, pharmacies compounding on a prescription basis are exempt from FDA's new-drug approval, labeling, and current good manufacturing practice requirements, and are instead overseen primarily by state boards of pharmacy ^[5]. Section 503B allows 'outsourcing facilities' to compound at larger scale under closer FDA oversight, including registration and inspection, but even those facilities don't run clinical trials on each formulation ^[6]. Practically, this means your protection comes from three places: the prescriber, the pharmacy's licensing and practices, and the ingredient supplier's own quality documentation. None of them is the FDA signing off on 'sirolimus for longevity.' That approval doesn't exist and isn't coming soon.

What should I check about the pharmacy itself?

Start with the state license. Every US pharmacy dispensing prescription drugs, including compounded sirolimus, must hold a license in the state where it operates and, for mail order, often in the state where the patient lives. You can look up most pharmacy licenses through the state board of pharmacy's public license search; the National Association of Boards of Pharmacy also maintains accreditation programs worth checking ^[1]. Ask or look for these specifics: - Is the pharmacy licensed in your state, more than its home state? Many states require an out-of-state (nonresident) pharmacy license for mail order.

• Does it operate under 503A (patient-specific compounding) or 503B (outsourcing facility)? 503B facilities register with FDA and are subject to routine inspection; that's a meaningfully higher bar than a 503A pharmacy operating on state oversight alone ^[6].
• Has the pharmacy had FDA warning letters or state board disciplinary actions? FDA publishes warning letters to compounders, and state boards publish disciplinary records; both are searchable. A pharmacy that won't tell you its state license number, or dodges the 503A/503B question, is a red flag regardless of how polished its marketing looks.

What lab documentation should a legitimate provider be able to show?

Ask for a Certificate of Analysis (CoA) for the specific batch or lot, not a generic marketing PDF. A real CoA lists the lot number, test date, identity confirmation (usually by HPLC or mass spec), potency (percent of labeled strength), and results for sterility or endotoxin testing if it's an injectable, plus impurity/degradation data. USP (United States Pharmacopeia) publishes compounding standards, most relevantly USP General Chapter 795 (nonsterile compounding) and 797 (sterile compounding), which set requirements for beyond-use dating, testing, and environmental controls that state boards commonly adopt by reference ^[6]. A pharmacy that can say its process follows USP 795/797 and back it up with batch-level CoAs is operating at a materially different standard than one that can't produce any lot-specific document at all. For context on why potency testing matters specifically for sirolimus: it's a narrow-ish therapeutic drug with a long half-life (roughly 57 to 63 hours in stable transplant patients according to the Rapamune label) , and blood level monitoring is standard practice in its approved transplant use. A compounded capsule that's actually 20% under or over labeled strength isn't a hypothetical problem, it changes your real exposure meaningfully given that long half-life.

How do I know the sirolimus source material itself is legitimate?

Compounding pharmacies buy active pharmaceutical ingredient (API) from bulk suppliers, and the API's own paperwork matters as much as the pharmacy's. Ask whether the API comes from an FDA-registered facility and whether the pharmacy can provide (or reference) the supplier's CoA for that specific API lot. Legitimate 503A pharmacies in the US are required to source bulk drug substances from FDA-registered facilities appearing on FDA's list of registered bulk drug substance facilities, and the substance generally needs to either meet a USP monograph (sirolimus has one) or be on FDA's list of bulk drug substances that can be used in compounding under Section 503A . If a provider can't tell you where the raw sirolimus comes from, that's not a small omission, it's the single biggest quality risk in the whole chain, bigger than dosing errors at the pharmacy bench.

What are the real risks of off-label rapamycin even from a 'clean' source?

Sourcing quality doesn't erase the biological risk profile, and buyers conflate the two constantly. Even a perfectly compounded, correctly dosed sirolimus capsule carries the drug's actual pharmacology. Immunosuppression is the headline risk, since sirolimus is fundamentally an immunosuppressant used to prevent transplant rejection ^[2]. At low, intermittent longevity-style doses the degree of immune suppression appears to be less than continuous transplant dosing, but there's no large controlled human safety dataset for that specific regimen; small trials and observational reports suggest weekly dosing may partially spare some immune function, but this is not settled . Mouth ulcers (stomatitis) are the most commonly reported side effect across sirolimus use generally, appearing in transplant trials at meaningfully higher rates than placebo, and anecdotally common in longevity users at lower doses too ^[2]. Metabolic effects are also real and dose-related: sirolimus can raise LDL cholesterol and triglycerides and has been associated with new-onset insulin resistance or hyperglycemia in transplant populations, per the Rapamune prescribing information's warnings and precautions section ^[2]. Anyone using it off-label should have baseline and follow-up lipid and glucose panels, more than take it and hope. None of that is a sourcing problem. It's a drug-risk problem that exists no matter how good your Certificate of Analysis is, which is why medical supervision, more than quality verification, is the other half of doing this responsibly.

What does the human longevity evidence actually say, and why does that matter for 'quality'?

It matters because a provider selling rapamycin for longevity is implicitly selling you on an outcome, and if that outcome claim is inflated, it should make you more skeptical of everything else they tell you, including their quality claims. The strongest evidence for rapamycin extending lifespan comes from mice, specifically the National Institute on Aging's Interventions Testing Program (ITP), which has tested rapamycin across genetically diverse mouse cohorts at three sites since 2006. Rapamycin has been the single most consistently replicated lifespan-extending intervention in that program, extending median lifespan in both sexes across multiple cohorts and starting ages, including when started relatively late in life . There is no completed human randomized controlled trial showing rapamycin extends human lifespan or healthspan. That's not a caveat, it's the whole story. The closest human data comes from short trials looking at immune response markers (like the 2014 Mannick et al. study in Science Translational Medicine, which found low-dose mTOR inhibition improved influenza vaccine response in older adults) and small studies of biomarkers like skin healing or periodontal measures, not lifespan or validated aging endpoints. A quality-verified batch of sirolimus is still a drug with mouse-level lifespan evidence and human-level uncertainty. Buying from a well-documented pharmacy doesn't change that gap; it just means the drug you're taking, whose long-term human longevity effect is unproven, is at least what the label says it is.

What questions should I actually ask a provider before I buy?

Use this as a literal checklist, in order of how much each answer should worry you if it's missing. 1. What state(s) are you licensed to dispense in, and can I verify that with the board of pharmacy? 2. Are you a 503A compounding pharmacy or a 503B outsourcing facility ^[6]? 3. Can I see a Certificate of Analysis for my specific lot, including potency and (for injectables) sterility testing? 4. Where does your sirolimus API come from, and is that facility FDA-registered ? 5. Do you follow USP 795/797 compounding standards, and can that be confirmed ^[6]? 6. Does a licensed prescriber review my labs (kidney function, lipids, glucose, CBC) before and during use? 7. What's your beyond-use date policy, and how is that determined? 8. Do you disclose that this use is off-label and that there's no completed human lifespan trial? A provider that answers all eight without hedging is rare, but it exists. A provider that gets defensive at question 4 or 8 has told you what you need to know.

How does compounded sirolimus differ from the FDA-approved Rapamune tablet?

The molecule is identical; the manufacturing pathway and oversight are not. Rapamune tablets and oral solution went through the full FDA New Drug Application process, meaning fixed, tested manufacturing, controlled bioequivalence, and continuous post-market surveillance ^[2]. A compounded capsule for off-label weekly dosing is made to order by a pharmacy, typically because the commercial tablet strengths (1mg is the smallest Rapamune tablet) don't match common longevity protocols that often use lower or differently-timed doses. That's a legitimate reason to compound; it isn't a workaround of a rule, it's literally what 503A compounding exists for (patient-specific needs the commercial product doesn't meet) ^[5]. But it does mean the burden of proving quality shifts from FDA's approval file onto the individual pharmacy's process, documentation, and testing. This is exactly why the checklist above matters more for compounded product than it would for a bottle of commercial Rapamune from a retail chain pharmacy. |Feature|FDA-approved Rapamune|Compounded sirolimus (503A)|

Where does dosing and protocol design fit into 'quality'?

Quality verification and correct dosing are different problems, but they compound each other. A perfectly pure, correctly labeled 6mg capsule is still the wrong thing to take if your protocol, frequency, or cycle length isn't matched to your labs and goals. If you're at the stage of comparing actual regimens, the Sirolimus Rx dosage page and the Sirolimus Rx dosage calculator walk through how intermittent weekly dosing protocols are typically structured, and Sirolimus Rx cycle length covers how long people typically stay on a given regimen before reassessing labs. If your product arrives as a lyophilized vial rather than capsules, reconstitution technique becomes its own quality checkpoint, since improper reconstitution can affect both potency and sterility regardless of how good the original CoA was; see how to reconstitute Sirolimus Rx for the mechanics. For injectable formulations, Sirolimus Rx how to inject and Sirolimus Rx injection sites cover technique questions that matter for both efficacy and avoiding local site problems.

What's the honest bottom line for someone about to buy?

Verify the pharmacy's license, ask for a lot-specific CoA, confirm 503A/503B status and USP compliance, and confirm the API source is FDA-registered. That's the concrete, checkable part, and most providers fail at least one of those checks if you push. Separately, and just as importantly: understand that you're buying an off-label drug with excellent mouse lifespan data from the NIA's Interventions Testing Program and no completed human lifespan trial. Quality verification tells you the pill is what it says it is. It does not tell you that taking it will extend your life, because nobody, including the companies selling it, has that data yet. Sirolimus Rx is provider-reviewed, meaning prescriptions are evaluated by a licensed clinician before dispensing, with fulfillment through a pharmacy partner rather than the platform compounding anything itself; ask any provider you're considering, including this one, the eight questions above and expect direct answers, not marketing language.

Frequently asked questions

Is Sirolimus Rx the same as rapamycin?

Yes. Sirolimus is the generic drug name; rapamycin is the original name given after its discovery from bacteria found on Rapa Nui (Easter Island). They refer to the same molecule. Brand names include Rapamune (oral, FDA-approved for transplant), Fyarro (IV, for a rare cancer), and Hyftor (topical gel, for tuberous sclerosis-related skin lesions) ^[1][3].

Is rapamycin FDA-approved for anti-aging or longevity use?

No. Rapamycin (as Rapamune) is FDA-approved only to prevent organ transplant rejection ^[2]. Fyarro and Hyftor are approved for narrow, unrelated conditions ^[3]. Any use for aging, lifespan extension, or general longevity is off-label, meaning a doctor can legally prescribe it that way, but the FDA has not reviewed or approved that specific use.

Has rapamycin been shown to extend human lifespan in a clinical trial?

No completed human trial has shown rapamycin extends lifespan. The strongest evidence is in mice, through the National Institute on Aging's Interventions Testing Program, which has repeatedly shown lifespan extension across genetically diverse mouse cohorts ^[12]. Human data is limited to short studies on biomarkers like immune response to vaccination ^[13], not lifespan or validated aging outcomes.

What is a Certificate of Analysis and why does it matter for sirolimus?

A Certificate of Analysis (CoA) is a lab document tied to a specific manufacturing lot showing identity confirmation, potency (percent of labeled strength), and, for sterile products, sterility and endotoxin results. For sirolimus specifically, potency matters because the drug has a long half-life (roughly 57-63 hours) ^[9], so under- or over-dosed batches meaningfully change real exposure over time.

What's the difference between a 503A and 503B compounding pharmacy?

503A pharmacies compound patient-specific prescriptions and are regulated mainly by state boards of pharmacy, exempt from FDA's cGMP and new-drug approval rules ^[5]. 503B outsourcing facilities compound at larger scale, register with FDA, and undergo routine FDA inspection ^[6]. 503B is generally a higher regulatory bar, though both can produce quality product if run well.

Where does the raw sirolimus (API) in compounded products come from?

Legitimate US compounding pharmacies must source bulk active ingredient from FDA-registered facilities, and the substance generally must meet a USP monograph or appear on FDA's approved list of bulk substances usable under Section 503A compounding ^[10]. Ask any provider directly where their API comes from; inability to answer is a serious red flag.

What are the real side effects of off-label low-dose rapamycin?

Mouth ulcers (stomatitis) are the most commonly reported side effect. Immunosuppression is the core pharmacological risk, though its degree at low intermittent doses versus continuous transplant dosing isn't fully established in controlled human trials ^[11]. Metabolic effects, including raised LDL cholesterol, triglycerides, and blood sugar, are documented in the Rapamune prescribing label ^[2].

Do I need blood work before and during rapamycin use?

Most clinicians overseeing off-label rapamycin protocols order baseline and periodic labs, typically kidney function, lipid panel, fasting glucose or HbA1c, and a complete blood count, given documented metabolic and immune effects in the approved transplant literature ^[2]. There's no universal official monitoring standard for longevity dosing specifically, since no regulatory body has approved this use.

How can I check if a pharmacy is actually licensed?

Check the pharmacy license lookup tool on the board of pharmacy website for the state where the pharmacy operates and the state where you live, since mail-order pharmacies often need a nonresident license in your state too. The National Association of Boards of Pharmacy also runs accreditation programs worth checking ^[7].

Why do longevity protocols use compounded sirolimus instead of the standard Rapamune tablet?

Because commercial Rapamune tablets come in fixed strengths (as low as 1mg) built for daily transplant dosing, not the lower or differently-timed doses used in common off-label weekly longevity protocols. Compounding lets a pharmacy match dose to a specific prescription, which is exactly the patient-specific purpose Section 503A compounding is meant for ^[5].

Does USP 795/797 compliance guarantee the product is safe?

No, but it's a meaningful floor. USP General Chapters 795 and 797 set standards for nonsterile and sterile compounding, including testing and environmental controls, that many state boards adopt into their regulations ^[8]. Compliance reduces contamination and potency-error risk; it doesn't address the separate, unresolved question of whether the drug achieves the longevity outcome users hope for.

Is buying rapamycin from an online longevity clinic legal?

It can be, if a licensed prescriber in a valid patient-provider relationship writes the prescription and a properly licensed pharmacy dispenses it, following state telehealth and pharmacy laws. Legality depends on state-specific rules for both prescribing and dispensing; verifying pharmacy and prescriber licensure directly, per the checklist above, is the only way to know for a specific provider.

Sources

1. National Institute on Aging, Interventions Testing Program overview: Sirolimus and rapamycin refer to the same molecule, and the ITP background on its origin and testing
2. FDA, Drugs@FDA database entries for Fyarro and Hyftor: Fyarro and Hyftor are FDA-approved sirolimus formulations for narrow, non-longevity indications
3. FDA, 'Understanding Unapproved Use of Approved Drugs "Off Label"': Definition and legality of off-label prescribing of an FDA-approved drug
4. National Association of Boards of Pharmacy (NABP), pharmacy accreditation programs: NABP maintains pharmacy accreditation and verification programs buyers can use to check legitimacy
5. USP, General Chapter <795> and <797> compounding standards overview: USP 795 and 797 set nonsterile and sterile compounding standards commonly adopted by state boards
6. Mannick JB et al., Science Translational Medicine (2014): Low-dose mTOR inhibition improved influenza vaccine antibody response in elderly subjects, the closest human data to an immune/aging benefit claim